According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “
CYAD has been the topic of several other reports. HC Wainwright cut their price target on shares of Celyad Oncology from $17.00 to $15.00 and set a buy rating on the stock in a report on Friday, August 6th. Jonestrading restated a hold rating on shares of Celyad Oncology in a report on Friday, August 20th.
A hedge fund recently bought a new stake in Celyad Oncology stock. OLD Mission Capital LLC acquired a new position in Celyad Oncology SA (NASDAQ:CYAD) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 11,323 shares of the company’s stock, valued at approximately $60,000. OLD Mission Capital LLC owned 0.07% of Celyad Oncology as of its most recent filing with the Securities & Exchange Commission. 1.83% of the stock is currently owned by institutional investors and hedge funds.
About Celyad Oncology
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms.
See Also: Understanding Options Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celyad Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad Oncology and related companies with MarketBeat.com's FREE daily email newsletter.